Zyla Life Sciences (OTCQX: ZCOR) is being acquired by Assertio Therapeutics, Inc. (NASDAQ GS: ASRT). Shareholders of Zyla will receive 2.5 shares of Assertio common stock for each share they own. The deal will require the shareholder approval of both companies. We are investigating whether more fulsome disclosures on valuation should be required here. To learn more, message me here or at jgrabar@grabarlaw.com.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.